• Kang-35 Yi-Yu capsules significantly improve total effective rate and clinical symptoms in rheumatoid arthritis patients.
• The combination therapy reduces inflammatory markers (ESR, CRP) and improves joint function.
• Adverse event rates are comparable to conventional therapy, indicating good safety profile.
• High-quality, multi-center randomized controlled trials are needed to strengthen the evidence base.